Bookmarks
Effectiveness of Indapamide Sustained Released on top of Perindopril on blood pressure change: a methodological study to validate effect of anti-hypertensive drugs in Clinical Research Practice Datalink
Safe People
Organisation name
Institut de Recherches Internationales Servier (IRIS)
Organisation sector
Commercial
Applicant name(s)
CELINE DARRICARRERE - Chief Investigator - IRIS - Institut de Recherches Internationales ServierCELINE DARRICARRERE - Corresponding Applicant - IRIS - Institut de Recherches Internationales Servierdominique Procureur - Collaborator - IRIS - Institut de Recherches Internationales ServierEmmanuelle Jacquot - Collaborator - IRIS - Institut de Recherches Internationales ServierJaume Aguado - Collaborator - RTI Health SolutionsMANEL PLADEVALL - Collaborator - RTI Health SolutionsMarie MANGIN - Collaborator - IRIS - Institut de Recherches Internationales ServierMorgane Ballon - Collaborator - IRIS - Institut de Recherches Internationales ServierStéphanie HENNEL - Collaborator - IRIS - Institut de Recherches Internationales ServierVirginie SIMON - Collaborator - IRIS - Institut de Recherches Internationales ServierXabier Garcia de Albeniz - Collaborator - RTI Health Solutions
Safe Projects
Project ID
CPRD464
Lay summary
Hypertension is a chronic condition characterized by high blood pressure. It represents one of the main risk factors leading to cardiovascular diseases. In England, hypertension affects approximately 30% of men and 26% of women. Clinical guidelines for hypertension first recommend changing some lifestyle factors that could have an impact on blood pressure. These changes may be followed by the prescription of medications for hypertension.
Technical summary
Hypertension is a chronic condition characterized by high blood pressure (BP) that affects 30% of men and 26% of women in England. It is a major contributing factor to cardiovascular outcome and reduction of elevated BP can decrease cardiovascular mortality. Perindopril (tert-butylamine 4mg or arginine 5mg) and indapamide Sustained Released (SR) 1.5mg are common hypertensive treatments.
Latest approval date
31/03/2021
Safe Data
Dataset(s) name
HES Admitted Patient Care
Patient Level Index of Multiple Deprivation
Safe Setting
Access type
Release